Access Official Technical PDF

Share Summary:LinkedInEmail

Patent aggregation—the acquisition or coordinated control of patents across a portfolio—can affect more than intellectual property ownership. For manufacturers and technology suppliers, it may change the licensing alternatives available, the cost of responding to infringement claims, and the resources devoted to product development. A 2020 antitrust complaint filed by Intel and Apple against Fortress Investment Group and affiliated entities described these concerns in the context of electronic devices and components. The claims were allegations in a legal filing, not judicial findings.

Why patent aggregation matters to technology suppliers

Complex products can incorporate many technologies, each of which may be covered by patents held by different owners. A supplier assessing a licensing demand must consider questions such as whether a patent applies to its product, whether the patent is valid and enforceable, and whether a different technical approach is available.

The complaint argued that separate patent owners can provide competing licensing options. If a supplier can seek a license from another owner of a patent covering an alternative way to perform a function—or redesign the product—it may have more leverage in negotiations. The filing alleged that bringing substitute patents under common control can reduce those alternatives and change the bargaining position of both licensors and licensees.

Substitute and complementary patents in a product portfolio

Understanding the complaint’s theory requires distinguishing between substitute and complementary technologies. Complementary technologies are used together to support a particular product design. Substitute technologies offer different ways to perform a shared function, although they may not be interchangeable in every application.

For example, one design might rely on technologies A, B and C, while another uses D, E and F. Within each design, the technologies work as complements. The two combinations may serve as substitutes if each can support the same product function. Other designs may mix technologies from both groups, making the relationships more complicated.

According to the complaint, a portfolio containing patents across these relationships can give its owner a broad set of licensing and assertion options. The plaintiffs alleged that when formerly independent owners of substitute patents come under common control, suppliers may lose the ability to negotiate among competing licensors. Whether a particular portfolio creates that effect depends on the patents, products and market circumstances involved.

How aggregation may change licensing and litigation incentives

The complaint also described how portfolio ownership could affect decisions about which patents to assert. When owners compete independently, a patent with uncertain validity, questionable relevance to a product, or an available design-around may offer limited licensing value. The filing alleged that aggregation can alter this calculation by allowing a patent to be asserted alongside other claims in a larger campaign.

For a target company, the burden may arise not only from the merits of an individual patent but from the time and cost of responding to multiple assertions. The complaint argued that repeated claims can make settlement attractive even when a target believes some patents are weak. That is an allegation about the effects of the defendants’ conduct in this case, not a general conclusion about every portfolio or patent assertion entity.

The filing further alleged that a network of affiliated patent-owning entities can make it harder for a prospective licensee to understand who controls particular rights or to obtain a comprehensive license from one counterparty. If a supplier must engage with multiple entities, it may face more negotiations or litigation proceedings. Clear ownership information and a precise account of the patents at issue are therefore important considerations in evaluating licensing exposure.

Implications for industrial automation decision-makers

Industrial automation products often depend on electronic components, software and interconnected systems. The complaint concerned electronic devices and related technologies, rather than industrial automation specifically, but the issues it raised are relevant to organizations that develop or integrate technology-rich products. Patent claims can affect companies across a supply chain, including component suppliers, equipment manufacturers and businesses incorporating third-party software or hardware.

For engineering, procurement, legal and operations teams, practical steps include:

  • Map technology dependencies. Keep a clear record of key components, software and external suppliers in a product or system.
  • Review licensing demands carefully. Identify the specific patents and product features at issue, rather than treating a broad portfolio description as proof of relevance.
  • Consider technical alternatives. Engineering teams can help determine whether a different design or implementation is feasible, while legal and commercial teams assess the associated costs and risks.
  • Clarify ownership and licensing scope. Confirm which entity controls the asserted rights and what products, affiliates or uses a proposed license covers.
  • Coordinate decisions across functions. IP disputes can involve engineering, finance, procurement and operations as well as legal counsel, so a shared assessment helps avoid disconnected decisions.

These measures do not determine whether a patent is valid or infringed. They help organizations assemble the technical and commercial information needed to assess a claim and decide how to respond.

Competition concerns and the limits of the allegations

The Intel and Apple complaint framed patent aggregation as an antitrust issue, alleging that control over competing patents could reduce licensing competition and increase royalties or litigation pressure. It also argued that additional licensing costs and legal expenses could divert resources from research and product development. These propositions were part of the plaintiffs’ case; a complaint sets out allegations, not established facts.

Patent ownership and portfolio licensing are not inherently anticompetitive. The relevant questions include whether patents that competed as licensing alternatives were brought under common control, what options remain for suppliers, and whether the conduct has effects that violate applicable law. Those questions require evidence about the specific patents, transactions and markets.

Conclusion: assess both the patent and the portfolio

For industrial technology suppliers, patent aggregation is worth monitoring because portfolio structure can influence licensing choices and the cost of responding to claims. The practical lesson is to assess asserted patents individually while also understanding ownership, related rights and available technical alternatives. A disciplined process involving engineering, legal and commercial teams can help decision-makers distinguish a specific technical risk from the broader pressure of a portfolio or litigation campaign.

Access Official Technical PDF

About The Author